The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor κB-dependent expression of antiapoptotic factors

Journal of Experimental Medicine

Volumn 194, Issue 9, 2001, Pages 1299-1311

  Akari, Hirofumi ^a,b   Bour, Stephan ^a   Kao, Sandra ^a   Adachi, Akio ^b   Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bcl xL; Caspase; TNF ; TRAF1; TrCP

Indexed keywords

CASPASE 3; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN A1; PROTEIN BCL XL; PROTEIN BFL 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VPU PROTEIN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTIGENS, CD4; APOPTOSIS; BCL-X PROTEIN; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BINDING SITES; CASPASE 3; CASPASES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; ENZYME ACTIVATION; GENE EXPRESSION; GENE PRODUCTS, ENV; GENE PRODUCTS, VPU; GTP-BINDING PROTEINS; HELA CELLS; HIV-1; HUMANS; JURKAT CELLS; NF-KAPPA B; PEPTIDE SYNTHASES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; SKP CULLIN F-BOX PROTEIN LIGASES; TNF RECEPTOR-ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035163739     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.9.1299     Document Type: Article

References (77)

1. Mechanisms of HIV-associated lymphocyte apoptosis
2. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest
3. Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells
4. Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection
5. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein
6. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release
7. Human immunodeficiency virus type 1 vpu protein induces rapid degradation of CD4
8. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments
9. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains
10. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses
11. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: Role of the cytoplasmic domain
12. Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD Env particle release activity
13. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: Implications for the mechanism of degradation
14. A novel human WD protein, h-βTrCP, that interacts with HIV-1 Vpu, connects CD4 to the ER degradation pathway through an F-box motif
15. Phosphorylation meets ubiquitination: The control of NF-κB activity
16. The human immunodeficiency virus type 1 Vpu protein inhibits NF-κB activation by interfering with β TrCP-mediated degradation of IκB
17. Control of apoptosis by Rel/NF-κB transcnption factors
18. Activators and target genes of Rel/NF-κB transcription factors
19. Macrophage colony-stimulating factor antagonists inhibit replication of HIV-1 in human macrophages
20. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
21. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
22. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl
23. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type 1 integral membrane protein
24. Generation of human monoclonal antibodies to human immunodeficiency virus
25. Human inmmnodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes
26. Regulating protein degradation by ubiquitination
27. The human immunodeficiency virus type 1 Vpu protein tethered to the CD4 extracellular domain is localized to the plasma membrane and is biologically active in the secretory pathway of mammalian cells: Implications for the mechanism of Vpu function
28. Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells
29. An essential role for NFκB in preventing TNF-α-induced cell death
30. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
31. Suppression of TNF-α-induced apoptosis by NF-κB
32. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control
33. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
34. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
35. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNF-α-induced apoptosis
36. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival
37. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis
38. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
39. Biochemical pathways of caspase activation during apoptosis
40. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
41. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death
42. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases
43. Modulation of cell death by Bcl-XL through caspase interaction
44. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins
45. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
46. + T cells in vivo by the induction of apoptosis?
47. Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing
48. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr
49. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation
50. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore
51. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels
52. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells
53. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden
54. + T lymphocytes and accessory cells in lymphoid tissues
55. Programmed death of T cells in HIV-1 infection
56. Differential susceptibility to activation-induced apoptosis among peripheral Thl subsets: Correlation with Bcl-2 expression and consequences for AIDS pathogenesis
57. The Th1-Th2 hypothesis of HIV infection: New insights
58. NF-κB activation and HIV-1 induced apoptosis
59. Chronology of genetic changes in the vpu, env, and nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques
60. Chemokines and chemokine receptors: Role in HIV infection
61. + T cells
62. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
63. Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons
64. Chemokine production in HIV-seropositive long-term asymptomatic individuals
65. Reduced rate of disease development after HIV-2 infection as compared to HIV-1
66. Analysis of lymphocyte cell death and apoptosis in HIV-2-infected patients
67. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: Correlation of T cell apopI P tosis with β2 microglobulin concentration and disease evolution
68. Persistent infection of macaques with simian-human immunodeficiency viruses
69. The simian immunodeficiency viruses
70. CD4 is retained in the endoplasmic reticulum by the human immununodeficiency virus type 1 glycoprotein precursor
71. Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1
72. Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gpl60 with CD4 blocks the movement and maturation of CD4 to the plasma membrane
73. Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity
74. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner
75. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein
76. Differences in the interaction of HIV-1 and HIV-2 with CD4
77. Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4